Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2023-03-31 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings
2023-03-31 English
Updates
Regulatory Filings
2023-03-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-02-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-02-17 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document contains financial performance data for quarterly and nine-month periods, including sales, expenses, EBITDA, and PAT figures. It also discusses cost savings, asset monetization, and loan reduction. The presence of quarterly and nine-month financial data, along with operational updates and key developments since the last call, indicates this is a comprehensive interim or quarterly financial report. The document length is 1828 characters, which is short but contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-02-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an announcement of a conference call hosted by Nuvama Wealth Management with the management of Orchid Pharma to discuss the company's Q3FY23 financial results. It includes details about the call timing, dial-in numbers, and contact information. There is no actual financial data or transcript of the call included, only the invitation and logistical details. This fits the definition of a Call Transcript (CT) only if it contained the full transcript, but since it is only an announcement of the call, it does not qualify as a transcript. It is not an earnings release (ER) because it does not contain financial highlights or results, only a notice of the call. Given the options, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories. Confidence is high because the document clearly is a call announcement without substantive financial content or transcript.
2023-02-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.